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Abstract
Background: There is a pressing need to understand better the extent and distribution of antimicrobial resistance on
a global scale, to inform development of effective interventions. Collation of datasets for meta-analysis, mathematical
modelling and temporo-spatial analysis is hampered by the considerable variability in clinical sampling, variable quality
in laboratory practice and inconsistencies in antimicrobial susceptibility testing and reporting.
Methods: The Microbiology Investigation Criteria for Reporting Objectively (MICRO) checklist was developed by an
international working group of clinical and laboratory microbiologists, infectious disease physicians, epidemiologists and
mathematical modellers.
Results: In keeping with the STROBE checklist, but applicable to all study designs, MICRO defines items to be included in
reports of studies involving human clinical microbiology data. It provides a concise and comprehensive reference for
clinicians, researchers, reviewers and journals working on, critically appraising, and publishing clinical microbiology datasets.
Conclusions: Implementation of the MICRO checklist will enhance the quality and scientific reporting of clinical
microbiology data, increasing data utility and comparability to improve surveillance, grade data quality, facilitate meta-
analyses and inform policy and interventions from local to global levels.
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Background
There is a global drive to combat the growing problem
of antimicrobial resistance (AMR) [1, 2]. To better
understand the extent of the situation, a key activity is
generation and analysis of high-quality surveillance data.
A specific goal of the World Health Organization
(WHO) and various funding agencies is to improve
AMR surveillance in low- and middle-income countries
(LMICs) [3]. There has been also a concerted effort to
maximise reporting and analysis of available human clin-
ical microbiology data [4]. However, the utility of many
existing AMR datasets is hampered by considerable vari-
ability in clinical sampling and laboratory practices [5],
along with readily demonstrable inconsistencies in anti-
microbial susceptibility testing (AST) data and reporting
[6, 7]. These issues result in difficulties in data interpret-
ation and significantly limit inter-study comparability
[8]. Examples of methodological and reporting issues
and problems that can arise are highlighted in Table 1.
To ensure that technically accurate and comparable
microbiology laboratory results are produced by
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: pault@tropmedres.ac
†Paul Turner and Andrew Fox-Lewis contributed equally to this work.
1Cambodia-Oxford Medical Research Unit, Angkor Hospital for Children, Siem
Reap, Cambodia
2Centre for Tropical Medicine and Global Health, Nuffield Department of
Medicine, University of Oxford, Oxford, UK
Full list of author information is available at the end of the article
Turner et al. BMC Medicine           (2019) 17:70 
https://doi.org/10.1186/s12916-019-1301-1
clinical diagnostic laboratories, various organisations
and documents provide guidance on quality manage-
ment (recently reviewed in [9]), antimicrobial suscep-
tibility testing procedures (e.g. Clinical and
Laboratory Standards Institute (CLSI) and European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines) and reporting of antimicrobial
susceptibility data [10, 11]. Formal accreditation of la-
boratory quality management by national and/or
international organisations (e.g. International Stan-
dards Organisation (ISO)) is not yet feasible for la-
boratories in all LMICs. However, use of standard
operating procedures and internal quality controls (to
ensure assays are performed reliably and yield
intended results) plus, if possible, participation in an
external quality assurance scheme (to periodically
monitor accuracy and to compare performance with
other laboratories) can ensure that such laboratories
perform to international quality standards [12].
Previous statements using the STROBE model
(Strengthening the Reporting of Observational Studies in
Epidemiology) [13] relating to infectious diseases have
already been issued, including STROBE-NI (neonatal
infections [14]), STROME-ID (molecular testing [15])
and STROBE-AMS (antimicrobial stewardship [16]). In
particular, STROBE-NI provides some guidance on
reporting of microbiological methods (checklist items
4.6–4.8) but is not comprehensive and may not be suffi-
ciently visible to those working on non-neonatal infec-
tions. As yet there are no general recommendations for
good scientific reporting of clinical microbiology meth-
odology and results, an area that this paper aims to
address.
Methods
Aims and use of MICRO
The proposed Microbiology Investigation Criteria for
Reporting Objectively (MICRO) framework described
herein is a checklist of items to be included in reports of
studies involving human clinical microbiology data, ori-
ginating from any region of the world, in countries of all
income levels. It provides a concise and comprehensive
reference for clinicians, researchers, reviewers and jour-
nals working on, critically appraising, and publishing
clinical microbiology datasets. It is intended to apply to
Table 1 Examples of frequently occurring problems in the generation and reporting of clinical antimicrobial resistance data
Issue Example
Failure to report key ‘bug-drug’ combinations For both CLSI and EUCAST methods, methicillin resistance in Staphylococcus aureus is determined in
the laboratory using cefoxitin (or historically oxacillin) resistance as a proxy [19, 20]. The cefoxitin/
oxacillin result is used to infer susceptibility for all beta-lactam drugs, except those with specific
activity against methicillin-resistant S. aureus (MRSA, i.e. ceftaroline). Thus, consistent reporting
of cefoxitin/oxacillin resistance is required for unambiguous comparison of MRSA proportions
between studies.
Reporting of antimicrobials tested
on a subset of isolates
The issue of first- and second-line AST panels can lead to inconsistent reporting of resistance
prevalence. In many instances, second-line agents (e.g. meropenem for Escherichia coli) are only
tested on a subset of isolates (e.g. only those resistant to third-generation cephalosporins, such as
ceftriaxone, or only in isolates from selected clinical specimens [19]) and reporting of incorrect over
all resistance proportions can occur if inappropriate denominators are selected. For example, 100 E.
coli isolates are tested against ceftriaxone and 10 (10%) are found to be resistant. These 10 isolates
are tested subsequently against meropenem and 1 is resistant. This could be reported as 1/10
(10%) or 1/100 (1%) meropenem resistance. Neither of these percentages may be correct.
Multi-drug resistance definition and reporting With the exception of Mycobacterium tuberculosis (resistance to isoniazid and rifampicin), definitions
of bacterial multi-drug resistance (MDR) have been poorly defined and applied. The definition of
MDR often reflects local AST selection and antibiotic availability and thus rates are difficult to
compare meaningfully [21]. MDR definitions for major bacterial pathogens have been proposed
recently but overall consensus is lacking for many species [10, 21, 22].
Changes to published antimicrobial
susceptibility breakpoints over time
Changes in the definition of resistance can result in misleading time trends and difficulties in
inter-study comparisons, if not explicitly dealt with during analysis. For example, the CLSI penicillin
minimum inhibitory concentration (MIC) breakpoints for Streptococcus pneumoniae were updated in
2008, resulting in an increased proportion of non-meningitis isolates being reported as susceptible
following the change [23].
Classification of infections by location Hospital-acquired infections (HAI) are frequently more drug resistant than community-acquired
infections (CAI) caused by the same organism [24, 25]. Failure to classify organisms by timing or
location of infection can lead to significant under- or over-estimation of AMR rates.
Selection of appropriate isolates to include
in analysis
Failure to account for screening specimens (e.g. swabs to determine extended spectrum
beta-lactamase Enterobacteriaceae colonisation) and/or duplicate clinical isolates from discrete
infection episodes can also result in significant overestimation of resistance [26].
Testing and reporting clinically inappropriate
bug-drug combinations
The inclusion of susceptibility data for drugs with limited in vivo activity for a given pathogen
(e.g. gentamicin and Salmonella Typhi) may lead to clinical confusion and could result in poor
treatment outcomes.
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the reporting of microbiology results in any clinical
study, not only observational studies, and thus, the term
STROBE has not been incorporated into the name. Im-
plementation of this checklist aims to enhance the scien-
tific reporting of clinical microbiology data, increasing
data utility to improve surveillance, grade data quality,
facilitate meta-analyses and inform policy and interven-
tions from local to global levels.
Development of MICRO
The MICRO framework has been developed by a work-
ing group of clinical and laboratory microbiologists, in-
fectious disease physicians, epidemiologists and
mathematical modellers working in the UK and various
LMICs, using an adaptation of recommended method-
ology [17] (Table 2). The need for a guideline was
mooted during informal meetings as a result of discus-
sions around the highly variable clarity and quality of
clinical microbiology and/or AMR data in manuscripts
submitted for peer-review. All pre-meeting steps were
open and non-anonymised: discussions occurred by tele-
conference and documents were iterated and circulated
electronically to the group.
Review of published microbiology datasets from LMICs in
South and South East Asia
Following on from identification of reporting problems
from reviews of microbiology data from Africa [5, 8],
published microbiology datasets from South and South
East Asia were extracted for the ongoing AMR compo-
nent of the Infectious Diseases Data Observatory-led
systematic review, ‘Mapping the aetiology of
non-malarial febrile illness globally in malaria-endemic
regions’ (PROSPERO registration CRD42016049281).
Details of the review search strategy are available at [18].
The review database was accessed on 17 June 2018, and
all 177 available datasets were assessed to determine
whether the following laboratory quality variables were
reported (summarised in Additional file 1):
 Laboratory EQA participation
 AST methodology: scheme and version/year
 Inclusion of internal quality control information for
AST testing
We further assessed each dataset to determine
whether any technically inconsistent AST results were
reported for the following WHO Global Antimicrobial
Resistance Surveillance System (GLASS) priority patho-
gens: Klebsiella pneumoniae, Salmonella spp., S. aureus
and S. pneumoniae. These four pathogens were selected
on the basis of being important AMR organisms glo-
bally, covering both Gram-negative and Gram-positive
species, with a range of demonstrable reporting prob-
lems resulting from deviations from international guide-
lines. The intention was to provide illustrative examples
of problems frequently encountered, with potentially im-
portant consequences, rather than identify the entire
range. Data extraction was performed by one author
(PS), and another author (PT) verified potential report-
ing deviations by re-review of the relevant source
manuscripts.
Laboratory quality data could be assessed for 112 stud-
ies. None of the studies included details of EQA
programme participation. Four fifths (93/112; 83%) pro-
vided details of an AST guideline: CLSI in almost all
cases. The year or version number was not recorded in
12/93 (13%). Use of QC organisms was documented in
only 24/112 studies (21%); 14 of these mentioned spe-
cific American Type Culture Collection (ATCC) strains.
Examples of deviations from accepted AST reporting
practice were detected for all organisms assessed:
 Staphylococcus aureus. Forty studies reported beta-
lactam (penicillin, cephalosporin and/or carba-
penem) susceptibility data for S. aureus. Of these,
only 15 (38%) specifically included oxacillin and/or
cefoxitin results. Several studies reported discordant
results for 3rd generation cephalosporins and carba-
penems, which would be expected to be more or less
identical given the common resistance mechanism.
Of note, six studies included susceptibility data for
ceftazidime, an anti-pseudomonal third-generation
cephalosporin with limited anti-Gram-positive activ-
ity which would not normally be tested against S.
Table 2 A summary of the MICRO framework development
steps (derived from [17])
Step Detail
Initial steps Identify the need for a guideline
Review the literature
• Identify previous relevant guidance
• Seek relevant evidence on the quality of
reporting in published research articles
• Identify key information related to the potential
sources of bias in such studies
Pre-meeting activities Identify participants
Conduct informal exercise to identify key issues
Generate a list of items for consideration at the
face-to-face meeting
Plan meeting, including preparation and of
dissemination of pre-meeting materials
Face-to-face
consensus meeting
Present and discuss results of pre-meeting
activities
Discuss the rationale for including items in
the checklist
Post-meeting
activities
Finalise the guidance statement
Prepare manuscript for publication
Turner et al. BMC Medicine           (2019) 17:70 Page 3 of 8
aureus: two reported susceptible isolates despite the
absence of CLSI breakpoints.
 Streptococcus pneumoniae. Two studies reported
testing gentamicin and identification of susceptible
isolates despite there being no breakpoints defined
by either EUCAST or CLSI for this ‘bug-drug’
combination. Minimum inhibitory concentration
(MIC) determination is required for confirmation of
reduced susceptibility to penicillin among S.
pneumoniae isolates by both CLSI and EUCAST
criteria. However, of the seven studies reporting
non-susceptible pneumococci, two reported this
phenotype based on oxacillin disk diffusion testing
alone and one confirmed penicillin MIC in only a
subset of oxacillin non-susceptible isolates.
 Klebsiella pneumoniae. Isolates were reported to be
ampicillin susceptible (5–62% of isolates tested) in 5/
11 (45%) studies reporting the species, despite
almost universal intrinsic resistance globally and
CLSI guidance to report all isolates as resistant [19].
 Salmonella spp. Despite absence of in vivo activity, and
a specific CLSI warning against reporting, 24/76 (32%)
studies reporting Salmonella spp. included results for
gentamicin. All but one study reported susceptible
isolates, ranging from 33 to 100% of isolates tested.
Checklist development
Group discussions took place on five occasions between
June 2017 and July 2018, where reporting issues, and po-
tential checklist items, were discussed by members of the
working group. The issues identified include all aspects
pertaining to the unambiguous reporting of clinical micro-
biology data, including terminology, clinical context and
sampling, organism identification and nomenclature, AST
methodology, AMR definitions, handling of duplicate iso-
lates and quality assurance (Table 3). This issue list was
circulated to a wider group of clinical microbiologists,
infectious diseases’ physicians, biomedical scientists
(laboratory microbiologists), laboratory managers, epide-
miologists and mathematical modellers (i.e. the authors of
this manuscript) in advance of a meeting held in Bangkok,
September 2018, where the final checklist was agreed. At
the time of this meeting, the group members were all
working at, or were associated with, clinical and/or re-
search institutions in Asia (Cambodia, Indonesia, Laos,
Myanmar, Nepal and Vietnam) or the UK.
Table 3 An overview of the MICRO checklist
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Table 4 The MICRO framework: a checklist of items that should be addressed in reports of studies involving human clinical
microbiology data
Item Number Recommendation
Methods
Study design 1* Specimen types: Describe the types of specimen included, i.e. clinical (e.g. blood cultures) or non-diagnostic surveillance
(e.g. admission and other screening swabs to diagnose carriage). If specimens were obtained for diagnostic reasons,
clinical syndromes should be described where possible, and specimens/isolates stratified by clinical syndrome.
2* Sampling period: State the collection timeframe for specimens yielding isolates for which data is reported, e.g. from
MM/YY to MM/YY to be able to identify variability between seasons.
3* Sampling strategy: Describe the strategy for specimen collection, e.g. asymptomatic screening, sampling of all febrile
patients, sampling at clinician discretion, sampling of specific patient groups and convenience sampling (e.g. use of
isolates from an existing sample repository). Specify whether sampling followed routine clinical practice or was protocol
driven. Classify specimens as from community-acquired (CAI) or hospital-acquired (HAI) infections. The definition of HAI
used (e.g. HAI defined by specimen collection > 48 h after hospital admission) should be provided and should use ideally
an international standard (e.g. US Centers for Disease Control [27, 28]).
4 Target organisms: Explicitly state which organisms/organism groups were included in the report. Nomenclature should
follow international standards (i.e. using approved genus/species names as summarised in the International Journal of
Systematic and Evolutionary Microbiology). Lists of approved bacterial names can be downloaded from Prokaryotic
Nomenclature Up-to-Date (https://www.dsmz.de/bacterial-diversity/prokaryotic-nomenclature-up-to-date.html) and the List
of Prokaryotic Names with Standing in Nomenclature (http://www.bacterio.net/). Organisms considered contaminants
should be listed, if appropriate (e.g. coagulase negative staphylococci or Corynebacterium spp. [29, 30]).
Setting 5* Geographical setting: Describe the geographical distribution of specimens/patients from which isolates were obtained,
at least to a country level, but preferably to a sub-national level or a geoposition.
6* Clinical setting: Describe the type and level of the healthcare facilities (e.g. primary, secondary, tertiary) from which
specimens were obtained. If stating a microbiology laboratory, the centres served by the laboratory should be specified.
Laboratory work 7 Specimen processing: If applicable, describe specimen collection and handling, processing and sub-culture methods for
all types of specimen included. For example, if reporting AST results for blood culture and cerebrospinal fluid culture
isolates, the processing of these specimens by the laboratory should be briefly explained, including how specimens are
sub-cultured, the media used, incubation conditions and duration. A summary of specimen processing steps
(e.g. pre-processing steps, nucleic acid extraction method (if applicable), amplification platform, contamination avoidance
strategy) should be provided for molecular-only workflows (e.g. to detect Mycobacterium tuberculosis and rifampicin
resistance using the Cepheid Xpert MTB/RIF system).
8* Target organism identification: Details of identification methodology should be reported briefly. Where identification
databases were used (e.g. bioMerieux API/bioMerieux VITEK-MS/Bruker Biotyper), the version should be specified.
In general, all pathogens should be identified to species level. In the case of Salmonella species, organisms should be
identified to at least the S. Typhi, S. Paratyphi, or non-typhoidal Salmonella (NTS) level. Strain subtyping methods should
be reported according to STROME-ID [15].
9* Antimicrobial susceptibility testing: Describe the antimicrobial susceptibility testing methods used, internal quality control
processes and their interpretation, with reference to a recognised international standard, e.g. CLSI, EUCAST. Where an
international standard was followed, the specific edition(s) of guidelines used should be referenced. Deviations from
standard methodology should be described, along with evidence of validation. Handling of any changes to interpretative
criteria during the sampling period should be documented. State whether the raw AST data (zone diameters and/or
minimum inhibitory concentrations) were re-categorised with updated breakpoints or left as-is.
10 Additional tests performed to identify resistance mechanisms: Describe the testing methods used for adjunctive/
confirmatory antimicrobial susceptibility tests, such as enzymatic/molecular assays (e.g. Xpert MTB/RIF, mecA PCR) and
inducible resistance assays, with reference to a recognised international standard, where available. Where an international
standard was followed, the specific edition of guidelines used should be referenced. Deviations from standard
methodology should be described, along with evidence of validation.
11* Antimicrobial resistance definitions: Define resistance for each antimicrobial class (i.e. are isolates in the ‘intermediate’
category included within ‘susceptible’ or ‘resistant’ or analysed as a distinct category). If using the term, define MDR (e.g.
≥ 1 agent in ≥ 3 classes tested). For each organism type, an MDR test panel must be defined, consisting of the minimum
panel of individual antimicrobial agents/classes against which an isolate must be tested for that isolate to be considered
tested for MDR status. Antimicrobials to which an organism is intrinsically resistant cannot be part of the test panel or
contribute to MDR status [10, 22].
Quality assurance 12* External quality assurance: State whether the microbiology laboratory participates in an external quality control
programme and, if so, provide scheme details. Examples include the UK National External Quality Assurance Scheme
(www.ukneqasmicro.org.uk) and the American College of Pathologists External Quality Assurance/Proficiency Testing
Program (https://www.cap.org/)
13 Accreditation: State whether the laboratory is accredited through a national or international body (e.g. the International
Standards Organisation, ISO) and specify which assays are covered in the accreditation.
Bias 14* Duplicate and sequential isolates: The strategy for accounting for duplicate and sequential isolates from the same patient
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Results
The MICRO checklist covers important aspects of report-
ing of clinical microbiology data. It is expected that it will
be used in conjunction with an appropriate overall study
reporting statement (e.g. STROBE). Items 1–13 cover key
aspects of study methodology whilst 14–20 focus on result
reporting (Table 4). Core items, i.e. those that would be
expected to be included in every circumstance, are indi-
cated by an asterisk. Non-core items might be appropri-
ately described in the manuscript Additional file 1.
Discussion
The use of the MICRO checklist will result in the clin-
ical microbiology and AST data from studies being re-
ported in a considerably more consistent manner. In
addition to its utility during preparation and peer review
of study manuscripts, this checklist will be also useful to
researchers when planning new studies. It will increase
data quality and will reduce the publication of uninter-
pretable results. Data harmonisation and opportunities
for sharing will be promoted. Report clarity will be im-
proved for non-specialist readers and the prospects for
meaningful comparisons between studies will be in-
creased. Indeed, an important use of the framework
would be to permit quality grading of datasets for
inclusion into meta-analyses. We envisage that there
might be five categories based purely on the laboratory
data (Table 5), although the quality criteria could be
modified depending on the intentions of the
meta-analysis.
The major limitations of this work are that we did not
perform an exhaustive literature review nor carry out a
Table 4 The MICRO framework: a checklist of items that should be addressed in reports of studies involving human clinical
microbiology data (Continued)
Item Number Recommendation
should be clearly detailed. Duplicate isolates are multiple isolates of the same phenotypic organism (i.e. same species and
same resistance profile) from the same patient on the same date cultured either from the same clinical specimen, or from
two separate clinical specimens, such as blood and CSF. Sequential isolates are isolates of the same phenotypic organism
from the same patient at different dates, such as blood cultures taken on different dates. Various strategies for the handling
of duplicate and sequential isolates exist [11], and the strategy used should be transparent as it will bias pooled resistance
results. For example, inclusion of all isolates (the ‘all isolate strategy’) has been shown to shift pooled resistance proportions
toward greater resistance, whilst inclusion of only the first isolate per patient (the ‘first isolate strategy’) or only the first
isolate per infection episode (the ‘episode-based strategy’) will shift pooled results toward susceptibility.
Results
15* Population: Describe the demographics of the population from which clinical specimens and subsequent isolates
have been obtained, disaggregating age and gender data.
16* Denominators: Patient and isolate denominators should be used appropriately to ensure clarity regarding the numbers
included in each analysis. Of particular importance is the reporting of resistance where first- and second-line AST panels
were used (i.e. not all isolates of a particular species were tested against all agents). For drugs where only a subset of
isolates were tested, reporting of a percentage without the numbers of isolates tested/resistant may be highly misleading.
17 Site/place of acquisition: AST data from CAI and HAI should be reported and analysed separately.
18* Reporting resistance proportions for single agent and class resistance: Proportions of resistant isolates should be reported
as number of isolates susceptible or resistant to a given antimicrobial agent/class out of actual number of isolates tested
for susceptibility to that agent/class.
19 Reporting multidrug resistance proportions: If defined, the proportion of MDR isolates should be expressed as the number
of MDR isolates out of the number of isolates tested (i.e. the number undergoing the MDR test panel specific to that
organism). Single agent/class resistance should be always be reported, regardless of MDR reporting.
Discussion
Limitations 20 Discuss any reasons why bias may have been introduced into the reported data, due to patient/specimen selection,
isolation of organisms, or otherwise. Consider factors which may have either introduced bias into the types of organisms
isolated or the antimicrobial susceptibility profiles, e.g. receipt of antimicrobials prior to specimen collection will reduce the
yield of certain species and also select for more resistant organisms.
*Core ‘must include’ items
Table 5 An example of quality grading criteria based on the
laboratory components of MICRO
Grade Detail
A Accreditation details provided
No ID or AST errors detected
B Accreditation details not provided
EQA participation confirmed
Organism ID and AST methodology completely described
No ID or AST errors detected
C Accreditation details not provided
EQA participation not confirmed
Organism ID and AST methodology completely described
No ID or AST errors detected
D Accreditation details not provided
EQA participation not confirmed
Organism ID and AST methodology partially described
No ID or AST errors detected
E Overt ID and/or AST errors detected/strongly suspected
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formal Delphi survey to inform the checklist items.
However, the reporting errors sought in the literature re-
view for South and South East Asia were the same as
those identified previously in datasets from Africa [5, 8].
Common themes arose early and agreement was reached
by repeated review with the final workshop allowing
consensus. The final checklist contains items that should
be readily available for a quality-assured clinical micro-
biology laboratory service. Thus, we feel confident that
the major issues are included. The checklist will be
piloted within the University of Oxford Tropical Net-
work, and we will engage actively with the EQUATOR
(Enhancing the QUAlity and Transparency Of health
Research) Network and relevant professional organisa-
tions to promote its use more widely. User comments
will be sought following publication and implementation
of the checklist. In particular, feedback from users in
non-Asian settings will be valuable. It is expected that
revision will be required in time. We expect that techno-
logical development will result in significant expansion
of guidance on reporting of molecular-only organism
identification and AST results.
Conclusions
In summary, given the threats to human health from
AMR globally, there is a pressing need to capture and
model existing infection data whilst new surveillance ini-
tiatives mature sufficiently. The MICRO checklist provides
a consistent and comprehensive reporting framework to
ensure that interpretation and meta-analyses of such data-
sets are meaningful.
Additional file
Additional file 1: Details of microbiology datasets from South and South
East Asia included in the review. For each study, the antimicrobial
susceptibility guideline details are summarised along with deviations from
expected reporting for four bug-drug combinations: Klebsiella pneumoniae-
ampicillin; Salmonella sp.-gentamicin; Staphylococcus aureus-beta-lactams;
and Streptococcus pneumoniae-penicillin. The Staphylococcus aureus-beta-
lactams combination includes any penicillin, cephalosporin or
carbapenem apart from penicillinase-labile drugs (benzylpenicillin,
phenoxymethylpenicillin, amoxicillin, ampicillin). (PDF 489 kb)
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